BioLife Solutions, Inc. (NASDAQ: BLFS) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 33.52 | EPS (ttm) | 1.03 | Insider Own | 24.01% | Shs Outstand | 48.86M | Perf Week | 10.81% |
| Market Cap | 1.69B | Forward P/E | 103.68 | EPS next Y | 0.33 | Insider Trans | -11.10% | Shs Float | 42.68M | Perf Month | 22.78% |
| Enterprise Value | 1.69B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 6.69% | Perf Quarter | 49.91% |
| Income | 50.46M | P/S | 16.47 | EPS this Y | 166.88% | Inst Trans | - | Short Ratio | 3.85 | Perf Half Y | 57.40% |
| Sales | 102.82M | P/B | 4.03 | EPS next Y | 127.19% | ROA | 11.27% | Short Interest | 2.86M | Perf YTD | 43.34% |
| Book/sh | - | P/C | 103.36 | EPS next 5Y | 86.76% | ROE | 13.29% | 52W High | 34.54 -0.29% | Perf Year | 64.34% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | 1.70% | 52W Low | 17.75 94.06% | Perf 3Y | 78.66% |
| Dividend Est. | - | EV/EBITDA | 172.27 | Sales past 3/5Y | 8.10% 14.87% | Gross Margin | 63.80% | Volatility | 2.86% 3.88% | Perf 5Y | -26.10% |
| Dividend TTM | - | EV/Sales | 16.39 | EPS Y/Y TTM | 50.00% | Oper. Margin | 7.25% | ATR (14) | 1.21 | Perf 10Y | 1550.48% |
| Dividend Ex-Date | - | Quick Ratio | 7.14 | Sales Y/Y TTM | 21.95% | Profit Margin | 49.06% | RSI (14) | 74.48 | Recom | 2.28 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.69 | EPS Q/Q | - | SMA20 | 12.03% | Beta | 1.89 | Target Price | 31.00 |
| Payout | 0.00% | Debt/Eq | 0.04 | Sales Q/Q | 16.67% | SMA50 | 21.56% | Rel Volume | 0.59 | Prev Close | 34.66 |
| Employees | 155 | LT Debt/Eq | 0.03 | Earnings | Nov 05 | SMA200 | 41.27% | Avg Volume | 1.12M | Price | 34.44 |
| IPO Date | Nov 22, 1989 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 140.00% 7.15% | Net Debt/EBITDA | -0.84 | Volume | 655,842 | Change | -0.63% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-27-26 | Downgrade | Stephens & Co. | Overweight → Equal Weight | $30 → $31 |
| Jul-23-26 | Reiterated | William Blair | $31 | |
| Jul-23-26 | Downgrade | Jefferies | Buy → Hold | $22 → $31 |
| Jul-23-26 | Downgrade | TD Cowen | Buy → Hold | |
| Jul-22-26 | Reiterated | Craig-Hallum | Buy | $30 → $31 |
| Jul-22-26 | Downgrade | HC Wainwright & Co. | Buy → Neutral | $32 → $31 |
| Jul-22-26 | Downgrade | Lake Street | Buy → Hold | $31 |
| Jan-05-26 | Reiterated | Northland Securities | Outperform | $34 |
| Nov-24-25 | Reiterated | HC Wainwright & Co. | Buy | $30 → $32 |
| Nov-15-24 | Reiterated | Stephens | Overweight | $30 |
BioLife Solutions, Inc. (BLFS) operates as a global provider of specialized bioproduction tools and services, primarily catering to the cell and gene therapy industry. Its market reach extends across the United States, Canada, Europe, the Middle East, Africa, and other international regions. The company's offerings are essential for various stages of biologic-based therapy development, spanning from foundational and applied research to large-scale commercial manufacturing. Key products include proprietary biopreservation media, such as HypoThermosol FRS and CryoStor, which are engineered to minimize delayed cell damage and death typically associated with preservation. Complementing these are the ThawSTAR products, an automated line of devices for thawing vials and cryobags, designed to precisely manage the heat and timing for optimal biologic material thawing. BLFS also provides innovative cloud-connected evo shipping containers for the passive storage and secure transport of temperature-sensitive biologics and pharmaceuticals. Additionally, its comprehensive range encompasses liquid nitrogen laboratory freezers, various cryogenic equipment and accessories, and specialized storage services for biological and pharmaceutical products. Products are distributed both directly to customers and through a network of third-party distributors. Established in 1987, BioLife Solutions, Inc. maintains its headquarters in Bothell, Washington.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 103 | 96 | 82 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 37 | 34 | 29 | — | — | — | — | — | — | |
| Gross Profit | 65 | 62 | 54 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 56 | 55 | 50 | — | — | — | — | — | — | |
| Research and Development | 9 | 8 | 8 | — | — | — | — | — | — | |
| Other Operating Expense | -7 | 0 | 3 | — | — | — | — | — | — | |
| Operating Income | 8 | -1 | -7 | — | — | — | — | — | — | |
| Interest Expense | 1 | 3 | 1 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 1 | -8 | -4 | — | — | — | — | — | — | |
| Net Income Before Taxes | 8 | -12 | -11 | — | — | — | — | — | — | |
| Income Taxes | -42 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | 51 | -12 | -20 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 51 | -12 | -11 | — | — | — | — | — | — | |
| Net Income | 51 | -12 | -20 | — | — | — | — | — | — | |
| EPS (Recurring) | 1.03 | -0.25 | -0.44 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.03 | -0.25 | -0.44 | — | — | — | — | — | — | |
| EPS (Diluted) | 1.02 | -0.25 | -0.44 | — | — | — | — | — | — | |
| EBITDA | 10 | 4 | 2 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 33.77 | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 16.39 | 12.09 | 14.56 | — | — | — | — | — | — | |
| Gross Margin | 63.11 | 64.58 | 65.85 | — | — | — | — | — | — | |
| Operating Margin | 7.77 | -1.04 | -8.54 | — | — | — | — | — | — | |
| Net Margin | 49.51 | -12.50 | -24.39 | — | — | — | — | — | — | |
| Shares Outstanding | 49 | 48 | 46 | — | — | — | — | — | — | |
| Market Capitalization | 1,688 | 1,161 | 1,194 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Casdin Partners Master Fund, L.P. | 10% Owner | May 21 '26 | Sale | 23.70 | 650,000 | 15,405,000 | 4,757,165 | May 21 |
| Casdin Partners Master Fund, L.P. | 10% Owner | May 20 '26 | Sale | 23.70 | 250,000 | 5,925,000 | 5,407,165 | May 21 |
| Casdin Partners Master Fund, L.P. | 10% Owner | May 19 '26 | Sale | 22.65 | 300,000 | 6,795,000 | 5,657,165 | May 21 |
| Foster Karen A. | Chief Quality and Operations | Mar 23 '26 | Sale | 19.17 | 2,577 | 49,401 | 108,758 | Mar 31 |
| Foster Karen A. | Chief Quality and Operations | Mar 09 '26 | Sale | 20.00 | 500 | 10,000 | 113,242 | Mar 09 |
| Foster Karen A. | Chief Quality and Operations | Mar 05 '26 | Sale | 20.15 | 96,923 | 1,952,998 | 113,742 | Mar 09 |
| Foster Karen A. | Chief Quality and Operations | Mar 03 '26 | Sale | 20.74 | 418 | 8,669 | 210,665 | Mar 05 |
| Werner Sean | Chief Technology Officer | Mar 03 '26 | Sale | 20.74 | 111 | 2,302 | 49,932 | Mar 05 |
| Mathew Aby J. | EVP & Chief Scientific Officer | Mar 03 '26 | Sale | 20.74 | 529 | 10,971 | 392,937 | Mar 05 |
| Wichterman Troy | Chief Financial Officer | Mar 03 '26 | Sale | 20.74 | 588 | 12,195 | 220,649 | Mar 05 |
| Aebersold Sarah | Chief Human Resources Officer | Mar 03 '26 | Sale | 20.74 | 219 | 4,542 | 93,360 | Mar 05 |
| Berard Todd | Chief Marketing Officer | Mar 03 '26 | Sale | 20.74 | 353 | 7,321 | 165,940 | Mar 05 |
| Wichterman Troy | Chief Financial Officer | Jan 06 '26 | Sale | 25.59 | 990 | 25,334 | 150,746 | Jan 08 |
| Foster Karen A. | Chief Quality and Operations | Jan 06 '26 | Sale | 25.59 | 335 | 8,573 | 191,984 | Jan 08 |
| Aebersold Sarah | Chief Human Resources Officer | Jan 06 '26 | Sale | 25.59 | 241 | 6,167 | 75,765 | Jan 08 |